Abstract Library

#2900 Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study

Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Pubul V, García-Cañamaque L, Aller J,

Keywords: Lu-177-DOTATATE, radionuclide, survival, treatment,

#2880 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry

Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carmona Bayonas A

Authors: Carmona-Bayonas A, Mitjavila Casanovas M, Belló P, Percovich J, Prieto A,

Keywords: PRRT, 177Lu-DOTATATE, radionuclide,

#2742 Anti-Tumor Effects of Semaphorin 4D Blockade Unravel a Novel Pro-Invasive Mechanism of Vascular Targeting Agents

Introduction: One of the main consequences of inhibition of neovessel growth produced by angiogenesis inhibitors is increased intratumor hypoxia. Growing evidence indicates that tumor cells escape from this hypoxic environment to better nourished locations, presenting hypoxia as a positive stimulus for invasion. Particularly, anti-VEGF/R therapies produce hypoxia-induced invasion and metastasis in a spontaneous mouse model of pancreatic neuroendocrine cancer, RIP1-Tag2.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Casanovas O

Authors: Zuazo-Gaztelu I, Pàez-Ribes M, Carrasco P, Martín-Mitjana L, Sallaberry J,

Keywords: Antiangiogenic therapies, Semaphorin 4D, Mouse models of NETs, Invasion and metastasis,

#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors

Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Isiangulova A, Khasanov R,

Keywords: neuroendocrine tumors, somatostatin analogues, target therapy, everolimus, systemic therapy,

#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population

Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Isiangulova A, Khasanov R, Enikeev R, Gordiev M,

Keywords: neuroendocrine tumors, gastrointestinal tumor, prognosis, gep-net, registry, overall survival,